GLP-1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis including the REWIND and PIONEER 6 trials

Topics: 

Citation
Giugliano D, et al. Diabetes Obes Metab 2019;21(11):2576-2580.